Insilico Medicine
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 6
- Formation Bio launches $600 million fund to advance clinical-stage drug assets
Formation Bio announced a $600 million drug development accelerator fund aimed at acquiring 10 to 15 Phase I or Phase II assets over the next three to five years. The company says it will use its AI systems and clinical operations team to advance the assets to key milestones within two to four years before selling them or partnering with large pharmaceutical companies. A wholly owned subsidiary will serve as the fund’s general partner, with Formation Bio committing its own capital. Limited partners include research foundations, endowments, hospitals and charities. The report says Formation Bio’s claimed AI development advantage has not been independently established. BCG’s 2024 figures put the Phase I success rate for AI-designed molecules at 80% to 90%, falling to about 40% at Phase II.
MIT科技评论中文 · 🔥 5 - Insilico Medicine reports preliminary Phase I data for ISM6331
Insilico Medicine said in a Hong Kong Stock Exchange announcement, reported by 36Kr, that it presented preliminary positive data from the first-in-human Phase I trial of ISM6331 in a rapid oral presentation at the 2026 ESMO Congress. ISM6331 is an investigational oral pan-TEAD inhibitor designed with the aid of the company’s Chemistry42 generative AI platform. With an August 14, 2026 data cutoff, the company reported a 40% objective response rate among evaluable mesothelioma participants receiving 130 mg once daily and a 68.2% disease control rate across the 30–130 mg range at the first tumor assessment.
36氪快讯 · 🔥 0 - Haoyuan Pharma’s AI Drug Discovery Strategy Meets Its CDMO Platform
TMTPost reports that Haoyuan Pharma is using its compound inventory and synthesis capabilities to support AI-designed drug candidates through the ABC partnership with Insilico Medicine and Mabwell Biopharma, alongside its MedChemAI screening and customization platform. Haoyuan reported 182,000 molecules in reserve as of June 2026 and operates a Chongqing ADC CDMO facility that opened in March 2025. The report says no disclosed AI-related orders have yet demonstrated commercial demand for this model.
钛媒体 · 🔥 0 - AI drug discovery pivots toward digital twins and virtual cells
A Huxiu AI reprint of a Shenlan Guan article reports that this autumn the AI drug discovery field's attention is shifting from molecule generation toward digital twins and virtual cells, with practitioners saying the direction has been repeatedly raised since summer and that many AIDD companies now describe plans to move into virtual cells. The report says that in early October Mark Zuckerberg's Biohub expanded its virtual biology program to $1.8 billion, working with the US Department of Energy, NIH and Google DeepMind to build public data infrastructure for virtual cell models, and that nearly 10 related funding deals have appeared in China since April 2026. It also lists bottlenecks: calibrated dynamic time-series quantitative single-cell data is scarce, single-cell sequencing yields only snapshots, and models struggle to pass wet-lab validation of extrapolation and drug-perturbation prediction; virtual clinical trials and digital-twin diagnostics also lack mature regulatory and review standards, and the business model remains unclear.
虎嗅 AI · 🔥 0 - AI pharma's pivotal test: Rentosertib Phase III readout due 2029
The article reports that Anew Labs, an AI drug-discovery company spun out of ByteDance, raised a $290 million first round at a $1.5 billion valuation, and that Anthropic has reportedly built a wet lab in the San Francisco Bay Area where Claude drives robots to run real biological experiments. It divides the AI pharma chain into three groups — upstream AI technology firms such as Insilico Medicine, midstream CRO/CDMO wet-lab service providers such as GenScript and Twist Bioscience, and downstream pharma companies including Fosun Pharma and Hengrui Pharmaceuticals — and cites brokerage estimates that AI can cut drug-discovery timelines by 70%-90% and total R&D cost by roughly 50%. The decisive test is Insilico's lead asset Rentosertib, whose Phase IIa showed a 98.4 mL mean lung-capacity gain at 60 mg versus a 20.3 mL decline in controls; its China Phase III began in July 2026 with 320 planned participants and top-line data expected in 2029.
36氪 人工智能 · 🔥 0 - AI drug design is flooding Chinese labs with wet-lab work
Anthropic's Claude designed 1,320 binding proteins against a dozen targets, which Adaptyv Bio and Twist synthesized and tested; 354 were confirmed to bind, a hit rate near 30% versus the traditional 10%–15%. The article argues that as AI pushes the marginal cost of molecular design toward zero, the first orders flow to lab-service providers: GenScript's AIDD revenue doubled year over year in H1 with gross margins about 20 points above its traditional protein-expression business, while XtalPi posted 803 million yuan in 2025 revenue, tripled and its first full-year profit. Meanwhile Washington is trying to pull early-stage R&D and clinical capacity back onshore via HHS's TrialBlazer plan and the BIOSECURE Act.
MIT科技评论中文 · 🔥 0
Experience and discussion from the community
Share my Insilico Medicine experienceAsk about Insilico Medicine
Nobody has shared their experience with Insilico Medicine yet.